De novo development of proteolytically resistant therapeutic peptides for oral administration


The oral administration of peptide drugs is hampered by their metabolic instability and limited intestinal uptake. Here, we describe a method for the generation of small target-specific peptides (less than 1,600 Da in size) that resist gastrointestinal proteases. By using phage display to screen large libraries of genetically encoded double-bridged peptides on protease-resistant fd bacteriophages, we generated a peptide inhibitor of the coagulation Factor XIa with nanomolar affinity that resisted gastrointestinal proteases in all regions of the gastrointestinal tract of mice after oral administration, enabling more than 30% of the peptide to remain intact, and small quantities of it to reach the blood circulation. We also developed a gastrointestinal-protease-resistant peptide antagonist for the interleukin-23 receptor, which has a role in the pathogenesis of Crohn’s disease and ulcerative colitis. The de novo generation of targeted peptides that resist proteolytic degradation in the gastrointestinal tract should help the development of effective peptides for oral delivery.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: Genetic encoding of double-bridged peptides by protease-resistant phage.
Fig. 2: Panning of double-bridged peptide libraries under protease pressure.
Fig. 3: Characterization and size reduction of F3, the most stable peptide.
Fig. 4: Structure analysis and impact of chemical bridges on stability.
Fig. 5: Stability and oral administration in mice.
Fig. 6: Stable IL-23R antagonists.

Data availability

The main data supporting the results of this study are available within the paper and its Supplementary Information. The data used to make the graphs in the figures are provided as Supplementary Information. Next-generation sequencing source data are available from figshare at Coordinates of the two X-ray structures have been deposited in the Protein Data Bank with accession numbers 6TWB and 6TWC.


  1. 1.

    Goldberg, M. & Gomez-Orellana, I. Challenges for the oral delivery of macromolecules. Nat. Rev. Drug Discov. 2, 289–295 (2003).

    CAS  Article  Google Scholar 

  2. 2.

    Moroz, E., Matoori, S. & Leroux, J. C. Oral delivery of macromolecular drugs: where we are after almost 100 years of attempts. Adv. Drug Deliv. Rev. 101, 108–121 (2016).

    CAS  Article  Google Scholar 

  3. 3.

    Pratley, R. et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet 394, 39–50 (2019).

    CAS  Article  Google Scholar 

  4. 4.

    Nielsen, D. S. et al. Orally absorbed cyclic peptides. Chem. Rev. 117, 8094–8128 (2017).

    CAS  Article  Google Scholar 

  5. 5.

    Aguirre, T. A. S. et al. Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials. Adv. Drug Deliv. Rev. 106, 223–241 (2016).

    CAS  Article  Google Scholar 

  6. 6.

    Räder, A. F. B. et al. Orally active peptides: Is there a magic bullet? Angew. Chem. Int. Ed. 57, 14414–14438 (2018).

    Article  Google Scholar 

  7. 7.

    Naylor, M. R., Bockus, A. T., Blanco, M. J. & Lokey, R. S. Cyclic peptide natural products chart the frontier of oral bioavailability in the pursuit of undruggable targets. Curr. Opin. Chem. Biol. 38, 141–147 (2017).

    CAS  Article  Google Scholar 

  8. 8.

    Gentilucci, L., De Marco, R. & Cerisoli, L. Chemical modifications designed to improve peptide stability: incorporation of non-natural amino acids, pseudo-peptide bonds, and cyclization. Curr. Pharm. Des. 16, 3185–3203 (2010).

    CAS  Article  Google Scholar 

  9. 9.

    Perry, A. F. et al. Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic. Proc. Natl Acad. Sci. USA 107, 14093–14098 (2010).

    Article  Google Scholar 

  10. 10.

    Wang, C. K. & Craik, D. J. Designing macrocyclic disulfide-rich peptides for biotechnological applications perspective. Nat. Chem. Biol. 14, 417–427 (2018).

    CAS  Article  Google Scholar 

  11. 11.

    Banga, A. K. Therapeutic Peptides and Proteins: Formulation, Processing, and Delivery Systems 3rd edn (CRC Press, 2015).

  12. 12.

    Kristensen, P. & Winter, G. Proteolytic selection for protein folding using filamentous bacteriophages. Fold. Des. 3, 321–328 (1998).

    CAS  Article  Google Scholar 

  13. 13.

    Sieber, V., Plückthun, A. & Schmid, F. X. Selecting proteins with improved stability by a phage-based method. Nat. Biotechnol. 16, 955–960 (1998).

    CAS  Article  Google Scholar 

  14. 14.

    Howell, S. M. et al. Serum stable natural peptides designed by mRNA display. Sci. Rep. 4, 6008 (2015).

    Article  Google Scholar 

  15. 15.

    Baeriswyl, V. & Heinis, C. Phage selection of cyclic peptide antagonists with increased stability toward intestinal proteases. Protein Eng. Des. Sel. 26, 81–89 (2013).

    CAS  Article  Google Scholar 

  16. 16.

    Kather, I., Bippes, C. A. & Schmid, F. X. A stable disulfide-free gene-3-protein of phage fd generated by in vitro evolution. J. Mol. Biol. 354, 666–678 (2005).

    CAS  Article  Google Scholar 

  17. 17.

    Kale, S. S. et al. Cyclization of peptides with two chemical bridges affords large scaffold diversities. Nat. Chem. 10, 715–723 (2018).

    CAS  Article  Google Scholar 

  18. 18.

    Wang, J., Yadav, V., Smart, A. L., Tajiri, S. & Basit, A. W. Toward oral delivery of biopharmaceuticals: an assessment of the gastrointestinal stability of 17 peptide drugs. Mol. Pharm. 12, 966–973 (2015).

    CAS  Article  Google Scholar 

  19. 19.

    Heinis, C., Rutherford, T., Freund, S. & Winter, G. Phage-encoded combinatorial chemical libraries based on bicyclic peptides. Nat. Chem. Biol. 5, 502–507 (2009).

    CAS  Article  Google Scholar 

  20. 20.

    Bane, C. E. & Gailani, D. Factor XI as a target for antithrombotic therapy. Drug Discov. Today 19, 1454–1458 (2014).

    CAS  Article  Google Scholar 

  21. 21.

    Rentero Rebollo, I., Sabisz, M., Baeriswyl, V. & Heinis, C. Identification of target-binding peptide motifs by high-throughput sequencing of phage-selected peptides. Nucleic Acids Res. 42, e169 (2014).

    Article  Google Scholar 

  22. 22.

    Gaffen, S. L., Jain, R., Garg, A. V. & Cua, D. J. The IL-23–IL-17 immune axis: from mechanisms to therapeutic testing. Nat. Rev. Immunol. 14, 585–600 (2014).

    CAS  Article  Google Scholar 

  23. 23.

    Bourne, G. T. et al. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases. US patent US9624268B2 (2015).

  24. 24.

    Sayago, C. et al. Deciphering binding interactions of IL-23R with HDX–MS: mapping protein and macrocyclic dodecapeptide ligands. ACS Med. Chem. Lett. 9, 912–916 (2018).

    CAS  Article  Google Scholar 

  25. 25.

    Patel, D. V. Protagonist therapeutics expands PTG-200 collaboration agreement with Janssen to include second generation oral IL-23 receptor antagonists. Bloomberg (8 May 2019);

  26. 26.

    Rentero Rebollo, I. & Heinis, C. Phage selection of bicyclic peptides. Methods 60, 46–54 (2013).

    CAS  Article  Google Scholar 

Download references


We thank B. Mangeat from the Ecole Polytechnique Fédérale de Lausanne (EPFL) Gene Expression Core Facility for help with next-generation sequencing, A. Reynaud, D. Hacker, L. Durrer and S. Quinche from the EPFL Protein Production and Structure Core Facility for help with protein expression and crystallization, and E. Simeoni, I. Desbaillets, G. Ferrand and C. Waldvogel of the EPFL Center of Phenogenomics (CPG) for help with mouse experiments. The financial contributions from the Swiss National Science Foundation grants (project grant 157842, NCCR Chemical Biology and project grant 169526) and the EPFL are gratefully acknowledged.

Author information




X.-D.K. and C.H. conceived the strategy for proteolytic phage display with double-bridged peptides. X.-D.K. established the phage selection procedure, cloned the libraries, performed the phage selections against FXIa, synthesized and characterized the peptides, expressed and purified FXIa and determined the X-ray structures. J.M. expressed and purified IL-23R, performed the phage selections against IL-23R and characterized the peptides. V.C. identified the d-proline mutant. F.P. collected X-ray data and analysed the structures. L.A.A. performed the NMR study. X.-D.K., K.D. and C.H. wrote the manuscript with help from all authors.

Corresponding author

Correspondence to Christian Heinis.

Ethics declarations

Competing interests

J.M., X.-D.K. and C.H. are inventors on a patent protecting the IL-23R antagonists.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Supplementary Information

Supplementary results, methods, figures and tables.

Reporting Summary

Supplementary Dataset 1

Source data for the figures.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kong, XD., Moriya, J., Carle, V. et al. De novo development of proteolytically resistant therapeutic peptides for oral administration. Nat Biomed Eng 4, 560–571 (2020).

Download citation

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing